Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector

July 10, 2026 10:35 AM EDT News Briefing Han­soh meets Phase 3 SCLC goal; FDA ap­proves Sanofi on-body in­jec­tor ENDPOINTS Plus, news about Hunt­ing­ton’s, Fate Ther­a­peu­tics and Bausch + Lomb. 🇨🇳 Han­soh touts Phase 3 suc­cess for GSK-part­nered ADC: The pro­gram, called risvu­tatug rezete­can or Ris-Rez … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER